Genrix Bio Partners with Cullinan Therapeutics for GR1803 License
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...
Cullinan Oncology
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...